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Established Facts
• Mycoplasma pneumoniae causes pneumonia predominantly in school-aged children and young adults.
• Neonatal pneumonia associated with M. pneumoniae has been very rarely reported.
Novel Insights
• Vertical transmission of Mycoplasma pneumoniae infection was demonstrated in this case, the first 
time with the detection of M. pneumoniae by PCR and immunohistochemistry in placental tissue.
• M. pneumoniae can be considered as possible cause of congenital pneumonia in addition to other my-
coplasmas (M. hominis) and ureaplasmas (U. urealyticum and U. parvum).
DOI: 10.1159/000490610
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Abstract
Mycoplasma pneumoniae is a significant cause of pneumonia 
in school-aged children and young adults. We report a case 
of neonatal M. pneumoniae pneumonia in a preterm child 
manifesting in the first hours of life. Vertical transmission was 
demonstrated by the detection of M. pneumoniae in in-
flamed placental tissue indicating chorioamnionitis.
© 2018 S. Karger AG, Basel
Introduction
Mycoplasma pneumoniae colonizes the upper respira-
tory tract [1] and causes pneumonia predominantly in 
school-aged children and young adults [2]. In contrast, 
other mycoplasmas and ureaplasmas colonize the uro-
genital tract, among which M. hominis, U. urealyticum, 
and U. parvum may cause ascending intrauterine infec-
tion that can lead to adverse pregnancy outcomes and/or 
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neonatal pneumonia [3, 4]. Here, we present a preterm 
infant with severe neonatal M. pneumoniae pneumonia 
acquired by vertical infection.
Case Report
A preterm male neonate weighing 1,500 g was delivered by a 
30-year-old woman at 29 4/7 weeks of gestation by cesarean section 
because of recurrent vaginal bleedings and premature contractions 
for 3 days. Antenatal steroid administration had been completed. 
The Apgar score was 2, 4, and 9 at 1, 5, and 10 min, respectively, and 
the umbilical artery pH was 7.31. He developed a severe respiratory 
distress syndrome (RDS) in the first hour of life requiring mechan-
ical ventilation and surfactant administration. Chest X-ray showed 
a granular appearance of both lungs with air bronchograms (Fig. 1a). 
Empiric antibiotic treatment with amoxicillin and gentamicin was 
immediately started. After 24 h, extubation was achieved and fol-
lowed by nasal continuous positive airway pressure treatment. An-
tibiotic treatment was discontinued based on negative blood cul-
tures and C-reactive protein within the normal range. Secondary 
respiratory distress developed on the second day of life (DOL) and 
necessitated re-intubation until DOL 4 and again from DOL 6 to 11. 
Chest X-ray on DOL 6 revealed multifocal opacifications and con-
solidations (Fig. 1b). Because of the atypical RDS presentation, an 
extensive diagnostic workup was performed: cultures from blood 
and tracheal aspirate were repeatedly negative for bacteria, as well 
as for fungi, as were cultures from urine for cytomegalovirus. There 
were no signs and symptoms of multiorgan involvement. Blood cell 
count showed a leukocytosis of 41 × 109/L after birth, which in-
creased to a maximum of 97 × 109/L on DOL 2 and consisted of 
mainly neutrophils, including immature granulocytes. There was 
no evidence of leukemia or transient myeloproliferative disorder. 
C-reactive protein remained normal over the course of disease.
The unclear situation led to a detailed review of the medical 
history during pregnancy: the mother recalled a mild respiratory 
tract infection with intractable cough at 20 gestational weeks last-
ing for a week, but this was left untreated. The diagnostic workup 
in the neonatal tracheal aspirate was extended by M. pneumoniae-
specific PCR as previously described [5]: M. pneumoniae DNA 
could be detected in tracheal aspirate on DOL 3 and in a second 
sample from nasopharyngeal aspirate after extubation on DOL 4. 
No DNA of M. hominis, M. genitalium, or Ureaplasma spp. was 
found in the tracheal aspirate by PCR, performed as described pre-
viously [6, 7]. Treatment with erythromycin was initiated orally on 
DOL 4 (50 mg/kg/dose 4 times a day) and switched to intravenous 
application from DOL 7 to DOL 18 (40 mg/kg/dose 4 times a day). 
Erythromycin treatment was paralleled by a steady and sustainable 
improvement of clinical and radiographic findings. Chest X-ray on 
DOL 9 returned almost to normal. On DOL 22, the white blood 
cell count was normal and serological testing using an enzyme-
linked immunosorbent assay (Serion GmbH, Würzburg, Germa-
ny) revealed M. pneumoniae-specific immunoglobulin (Ig) M and 
IgG antibodies of < 5 U/mL (cutoff 17 U/mL) and 65 U/mL (cutoff 
15 U/mL), respectively. Nasal continuous positive airway pressure 
treatment was followed until DOL 23 and supplemental oxygen 
administered until DOL 30, defining mild bronchopulmonary 
dysplasia. The infant was discharged with 8 weeks of age at 37 6/7 
weeks postmenstrual age. A 1-month follow-up was uneventful.
Maternal serum obtained 2 weeks after birth was tested positive 
for M. pneumoniae-specific IgM (93 U/mL; cutoff 17 U/mL) and 
IgG (> 200 U/mL; cutoff 30 U/mL), indicating a recent infection. 
Prepartal maternal swabs from the cervix uteri were negative by 
PCR for DNA of Chlamydia trachomatis and Neisseria gonorrhoe-
ae, and also vaginal swab cultures were negative. Histological ex-
amination of the placenta showed distinct chorioamnionitis and 
vasculitis with infiltration of neutrophils into the chorioamniotic 
mesoderm layer and amnion (Fig. 1c, e). Placental tissues embed-
ded in paraffin were tested positive for M. pneumoniae DNA by 
PCR and M. pneumoniae antigens by immunohistochemistry 
(Fig. 1d, f). Placental tissue was tested negative for DNA of Urea-
plasma spp., M. hominis, and M. genitalium by PCR. Control pla-
cental tissues without chorioamnionitis and chorioamnionitis of 
other origin were tested negative for M. pneumoniae antigens by 
immunohistochemistry (data not shown).
Discussion
Congenital pneumonia arises from direct mucosal 
seeding from infected amniotic fluid (chorioamnionitis), 
which is caused by hematogenous transplacental infec-
tion or ascending infection across the chorioamniotic 
membranes [8]. Maternal vaginal colonization is a key 
risk factor for an ascending intrauterine infection and/or 
perinatal infection during passage through the birth canal 
[8]. Mycoplasmas are primarily mucosal pathogens, 
among which genital mycoplasmas and ureaplasmas col-
onize the urogenital tract. M. hominis, U. urealyticum, 
and U. parvum are also associated with neonatal pneumo-
nia [3, 4]. In contrast, M. pneumoniae is known to exclu-
sively colonize the respiratory tract [3]. The question aris-
es whether chorioamnionitis in our case was caused by a 
so far not reported ascending infection or rather by spread 
from respiratory tract infection through the bloodstream 
to the placenta. In line with the latter, M. pneumoniae has 
been reported to disseminate in the bloodstream during 
or after a respiratory tract infection and to cause extrapul-
monary manifestations [9–12]. The mother indeed expe-
rienced a cough around 8 weeks before birth and the se-
rology after birth confirmed a recent M. pneumoniae in-
fection. This respiratory infection may have led to invasive 
infection and spread of M. pneumoniae to the placenta. 
In fact, infections with M. hominis, U. urealyticum, or U. 
parvum as potential cause of adverse pregnancy outcome 
and/or neonatal pneumonia were excluded. Thus, the di-
agnosis of vertical M. pneumoniae infection in our case is 
established as follows: (1) maternal respiratory tract in-
fection at 20 gestational weeks with strongly positive M. 
pneumoniae serology 2 weeks after birth; (2) detection of 
M. pneumoniae in placental tissue by PCR and immuno-
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Fig. 1. a Chest X-ray, on day of life (DOL) 1, showing a diffuse interstitial pattern with granular appearance and 
air bronchograms of both lungs. b Chest X-ray, on DOL 6, showing reticular (bullous) multifocal opacifications 
and consolidations. c, e Chorioamnionitis with infiltration of neutrophils (arrows) into the chorioamniotic me-
soderm layer and amnion. Hematoxylin and eosin stain. Original magnification ×100 (c) and ×400 (e). d, f Im-
munohistochemical analysis of placental tissue performed by using a biotinylated polyclonal anti-M. pneumoni-
ae antibody (Thermo Scientific, Waltham, MA, USA) and an avidin-biotin-peroxidase complex with 3,3-diami-
nobenzidine tetrahydrochloride chromogenic substrate showing positive staining in the chorioamniotic 
mesoderm layer and amnion. Original magnification ×100 (d) and ×400 (f).
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histochemistry; (3) detection of M. pneumoniae by PCR 
from neonatal respiratory specimens on DOL 3 and 4; 
and (4) neonatal pneumonia manifesting in the first 
hours of life and presenting as atypical RDS.
Invasive M. pneumoniae infection is rare [10], and ver-
tical transmission of M. pneumoniae infection has been 
very rarely reported. To our knowledge, 3 cases of neona-
tal pneumonia associated with M. pneumoniae have been 
published so far (Table 1) [13–15]. Vertical transmission 
of M. pneumoniae infection has been suggested in 2 pre-
term neonates with either rapidly or slowly progressing 
respiratory failure requiring mechanical ventilation im-
mediately after birth. A vertical route of transmission was 
confirmed in 1 case with the detection of M. pneumoniae 
DNA by PCR in placental tissue. We additionally showed 
by immunohistochemical analysis that M. pneumoniae is 
present in the placenta.
Interestingly, anti-M. pneumoniae IgG, but not IgM, 
was detected in the neonate on DOL 22. The detection of 
specific IgG is complicated by transplacental transfer of 
maternal antibodies. In contrast, the detection of IgM is 
very specific to the fetal compartment because IgM does 
not cross the placenta. However, the neonate’s immune 
system may not mount an antibody response as effective 
as adults [16], and, most importantly, a negative IgM re-
sult does not exclude congenital infection [17, 18]. Fur-
ther, the antibody response to M. pneumoniae is complex 
[19]. We present only the second case of neonatal pneu-
monia associated with M. pneumoniae, in which the an-
tibody response was assessed (Table 1). One might specu-
late that the presence or absence of M. pneumoniae-spe-
cific IgM may discriminate between perinatal infection 
after birth (case 3, Table 1) and congenital infection (pres-
ent case).
This case demonstrates that M. pneumoniae can be 
considered as possible cause of congenital pneumonia in 
addition to other “atypical” organisms. The route of 
transmission of M. pneumoniae is vertical infection after 
dissemination of the bacteria following maternal respira-
tory tract infection. Chorioamnionitis likely induced pre-
mature birth, but it remains unclear whether M. pneu-
moniae triggered also bronchopulmonary dysplasia as re-
ported for ureaplasmas.
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